- Home
- ACAD vs ODD Comparison
ACAD vs ODD Comparison
Compare ACAD & ODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- ODD
- Stock Information
- Founded
- ACAD 1993
- ODD 2018
- Country
- ACAD United States
- ODD Israel
- Employees
- ACAD N/A
- ODD N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- ODD
- Sector
- ACAD Health Care
- ODD
- Exchange
- ACAD Nasdaq
- ODD Nasdaq
- Market Cap
- ACAD 2.5B
- ODD 2.3B
- IPO Year
- ACAD 2004
- ODD 2023
- Fundamental
- Price
- ACAD $17.44
- ODD $71.00
- Analyst Decision
- ACAD Buy
- ODD Buy
- Analyst Count
- ACAD 15
- ODD 8
- Target Price
- ACAD $24.21
- ODD $54.63
- AVG Volume (30 Days)
- ACAD 1.8M
- ODD 1.1M
- Earning Date
- ACAD 05-07-2025
- ODD 04-29-2025
- Dividend Yield
- ACAD N/A
- ODD N/A
- EPS Growth
- ACAD N/A
- ODD 45.36
- EPS
- ACAD 1.37
- ODD 1.74
- Revenue
- ACAD $996,283,000.00
- ODD $703,488,000.00
- Revenue This Year
- ACAD $13.07
- ODD $22.39
- Revenue Next Year
- ACAD $10.06
- ODD $20.09
- P/E Ratio
- ACAD $12.74
- ODD $40.88
- Revenue Growth
- ACAD 22.42
- ODD 26.83
- 52 Week Low
- ACAD $13.40
- ODD $32.71
- 52 Week High
- ACAD $20.68
- ODD $69.96
- Technical
- Relative Strength Index (RSI)
- ACAD 67.70
- ODD 84.66
- Support Level
- ACAD $14.45
- ODD $39.55
- Resistance Level
- ACAD $15.31
- ODD $43.14
- Average True Range (ATR)
- ACAD 0.69
- ODD 3.73
- MACD
- ACAD 0.37
- ODD 2.35
- Stochastic Oscillator
- ACAD 94.92
- ODD 99.78
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.